BioVex Begins Dosing in Melanoma Trial
Posted on: Thursday, 16 February 2006, 21:00 CST
The first patients in BioVex' phase II trials of OncoVex GMCSF in malignant melanoma and in head and neck cancer have received their initial doses of the therapeutic treatment.
The melanoma trial is a 50 patient multi-center study. The first dosing took place at the Mary Crowley Medical Research Center, Dallas, Texas. The primary endpoint of the study is tumor response rate with secondary endpoints including time to disease progression and median survival time.
The head and neck cancer trial is a 16% open label study in combination with chemoradiotherapy. It is being carried out at the Royal Marsden Hospital in London, UK. The first patient in this trial has recently completed the seven week dosing regime.
The end point of the trial is to assess the safety of OncoVex GMCSF combined with chemoradiotherapy, and the potential of OncoVEX as neoadjuvant therapy in the treatment of head and neck cancer. Preliminary results from both trials will be available in late 2006.
OncoVEX GMCSF is an oncolytic virus that selectively kills tumor cells. In addition it induces tumor cells to secrete GMCSF, to enhance tumor destruction. The drug has completed a phase I/II study in several solid tumors including breast cancer, head and neck cancer, gastro-intestinal cancer and melanoma. Results from the administration of OncoVEX GMCSF in either single or multiple doses have shown the product to be well tolerated. Substantial biological effects, including tumor necrosis, were also observed.
Commenting on the melanoma trial, principle investigator Dr Nemuniatis said: "Melanoma is a problem of increasing seriousness and BioVex's unique strategy using a dual approach of a potent oncolytic agent, coupled with the local release of a powerful cytokine may offer an important advance in our understanding of treatment options."
Source: Datamonitor
Related Articles
- Depomed Reports Positive Efficacy Data From a Phase 2 Trial of Gabapentin GR(TM) in the Treatment of Menopausal Hot Flashes
- ANAVEX 7-1037 Demonstrates Chemotherapeutic Potential Without Toxic Side Effects for the Treatment of Colorectal Cancer, Other Types of Solid Tumors
- SciClone's SCV-07 Inhibits Melanoma Tumor Growth in Animal Model Study
- Cell Therapeutics, Inc. (CTI) Closes PGT305 (PIONEER) Lung Cancer Clinical Trial; New PGT306 Protocol to Be Submitted to FDA By Year End
- Head/neck skin cancer tied to chronic sun exposure
- Threshold Pharmaceuticals Completes Enrollment in Phase 3 Study for the Treatment of Benign Prostatic Hyperplasia
- Study looks at factors influencing African-American women's decisions to join cancer screening trial
- Cancer Misdiagnosed in 12% of Cases: Study
- Genetically Modified Virus May Help Treat Brain Tumors: Study
- Vitamin E Scare Hurts Cancer Trial; Doctors Say Their Study on Supplement, Prostate Cancer Prevention is Safe
 |
 |
User Comments (0)
RSS Feeds